Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

Enrollment in phase II clinical trial of brentuximab vedotin for ALCL completed

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced that they have completed enrollment of a phase II clinical trial of brentuximab vedotin (SGN-35) for relapsed or refractory systemic anaplastic large cell lymphoma.

24 May 2010

Filing of Clinical Data's NDA for vilazodone accepted for FDA review

Clinical Data, Inc., today announced that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application for vilazodone for the treatment of major depressive disorder.

24 May 2010

Raw alfalfa sprouts linked to outbreak of Salmonella Newport infections in 10 states

Caldwell Fresh Foods of Maywood, Calif., is voluntarily recalling all of its alfalfa sprouts marketed under the Caldwell Fresh Foods, Nature's Choice, and California Exotics brands. The firm's alfalfa sprouts have been linked to an outbreak of Salmonella Newport infections in consumers in ten states.

24 May 2010

New findings on INTUNIV Extended Release Tablets presented at major psychiatric meeting

Shire plc, the global specialty biopharmaceutical company, today announced new findings on once-daily INTUNIV (guanfacine) Extended Release Tablets, the first selective alpha-2A agonist approved for the treatment of Attention Deficit Hyperactivity Disorder, at a major psychiatric meeting.

24 May 2010

PTCL trial data on belinostat to be presented at 2010 ASCO Annual Meeting

Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in hematology and oncology, today announced that clinical data on belinostat will be presented at the 2010 Annual Meeting of the American Society of Clinical Oncology, to be held June 4-8, 2010 at the McCormick Place Convention Center in Chicago, Illinois, as part of the ASCO proceedings.

21 May 2010

Data evaluating use of nab-paclitaxel for treatment of pancreatic cancer to be presented at ASCO 2010

Abraxis BioScience, Inc., a fully integrated biotechnology company, previously announced it will be presenting more than 30 studies, including new clinical data evaluating the use of nanoparticle albumin bound driven chemotherapy, nab-paclitaxel (ABRAXANE for Injectable suspension; paclitaxel protein albumin-bound particles for injectable suspension) for the treatment of pancreatic cancer at the 46th Annual Meeting of the American Society of Clinical Oncology in Chicago.

21 May 2010

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Pfizer Oncology will present new data highlighting the company's focused approach to cancer drug development through the identification and validation of molecular targets. These results will be presented at the 46th Annual American Society of Clinical Oncology meeting in Chicago from June 4-8.

21 May 2010

Vitamin D plays much wider role in people's life

Vitamin D is the sunshine vitamin - we make it when our skin is exposed to UV rays. In a perfect world everyone would eat fresh, organic foods, get outside, and enjoy a little sunshine all year round. But with today's busy lifestyles and concerns about skin cancer many people are vitamin D deficient and don't know it.

21 May 2010

Eli Lilly to present results of two Phase II trials evaluating ALIMTA in combination with chemotherapy, radiation

Results of two Phase II trials evaluating ALIMTA (pemetrexed for injection) in combination with a platinum chemotherapy and radiation for patients with locally advanced non-small cell lung cancer will be presented by Eli Lilly and Company at the 46th Annual Meeting of the American Society of Clinical Oncology in Chicago, Ill., on June 6, 2010.

21 May 2010

Genentech to present new data for targeted cancer medicines at 46th ASCO

Genentech, Inc., a wholly owned member of the Roche Group, today announced that it will present new data for its targeted cancer medicines and the way they may be used in several different cancer types at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Approximately 400 abstracts featuring Genentech and Roche's cancer medicines and investigational agents across 30 cancer types will be presented during the meeting that is taking place June 4 to 8, 2010 in Chicago.

21 May 2010

Data from Phase 3 clinical trials of PROVENGE in advanced prostate cancer to be presented at ASCO 2010

Dendreon Corporation today announced the upcoming presentation of data from integrated analyses of three Phase 3 PROVENGE (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in advanced prostate cancer, to be presented at the annual meeting of the American Society of Clinical Oncology in Chicago on Monday, June 7 at 8:00 a.m. CT.

21 May 2010

Long-term data demonstrates clinical benefits of Exelixis XL184 for medullary thyroid cancer

Exelixis, Inc. today reported long-term results in a cohort of 37 medullary thyroid cancer (MTC) patients who participated in the phase 1 study of XL184. Dr. Razelle Kurzrock from the MD Anderson Cancer Center in Houston, TX will present the data in a Clinical Science Symposium (Abstract #5502) on Monday, June 7 at 10:15 AM at the 2010 Annual Meeting of the American Society of Clinical Oncology in Chicago.

21 May 2010

Canadian Cancer Statistics 2010 focuses on care, support for dying patients

The type and quality of care and services to ensure a cancer patient dies with dignity in the setting of their choice depends on where the person lives in Canada, according to a special report about end-of-life care in Canadian Cancer Statistics 2010, released today by the Canadian Cancer Society.

20 May 2010

A.P. Pharma receives Nasdaq non-compliance notice

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on May 18, 2010, the Company received a letter from The Nasdaq Stock Market (Nasdaq) indicating that the minimum closing bid price of its common stock had fallen below $1.00 for 30 consecutive trading days, and therefore, A.P. Pharma was not in compliance with Marketplace Rule 5550(a)(2).

20 May 2010

Allergy sufferers can save out-of-pocket costs by visiting urgent care and retail health clinics instead of ER

In this economy, allergy sufferers are looking for relief from more than sneezing, runny noses, and itchy eyes. And, according to a recent study, they can find relief for both their symptoms and their wallets, saving anywhere from $50 to $400 in out-of-pocket costs per visit if they skip the emergency room and head to urgent care and retail health clinics when they are unable to see their primary physician.

20 May 2010

Research shows improved treatment of severe epilepsy reduces overall cost of the condition

Improved treatment of severe epilepsy could reduce the overall cost of the condition, according to research presented at the annual meeting of the International Society of Pharmacoeconomic Outcomes Research at the Hilton Atlanta in Atlanta, Georgia.

20 May 2010

Studies suggest potent therapeutic effects of rufinamide in bipolar disorder, depressive and anxiety disorders

This study formulates the hypothesis that rufinamide, a drug so far used against epilepsy, may also be effective in bipolar disorder, depressive and anxiety disorders, panic disorder and obsessive-compulsive disorder, eating disorders, and substance use disorders. It is just an hypothesis based on two cases that needs to be confirmed by specific studies.

19 May 2010

DanActive drink reduces rate of common sicknesses in daycare children, say researchers

The probiotic yogurt-like drink DanActive reduced the rate of common sicknesses such as ear infections, sinusitis, the flu and diarrhea in daycare children, say researchers who studied the drink in the largest known probiotic clinical trial to be conducted in the United States. An additional finding, however, showed no reduction in the number school days missed.

19 May 2010

Flibanserin benefits pre-menopausal women with Hypoactive Sexual Desire Disorder

Data from pivotal Phase III clinical trials demonstrate that a higher proportion of pre-menopausal women with Hypoactive Sexual Desire Disorder (HSDD) receiving flibanserin 100mg reported both an improvement in their condition and a meaningful benefit from their treatment, compared to placebo.

19 May 2010

Columbia Laboratories renews license and supply agreement with Merck Serono

Columbia Laboratories, Inc. has renewed its license and supply agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, for CRINONE (progesterone gel) for an additional five-year term. Under the existing agreement and the renewal, Merck Serono has marketing rights worldwide, except the United States.

18 May 2010

Nausea News and Research

Further Reading

Enrollment in phase II clinical trial of brentuximab vedotin for ALCL completed

Filing of Clinical Data's NDA for vilazodone accepted for FDA review

Raw alfalfa sprouts linked to outbreak of Salmonella Newport infections in 10 states

New findings on INTUNIV Extended Release Tablets presented at major psychiatric meeting

PTCL trial data on belinostat to be presented at 2010 ASCO Annual Meeting

Data evaluating use of nab-paclitaxel for treatment of pancreatic cancer to be presented at ASCO 2010

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Vitamin D plays much wider role in people's life

Eli Lilly to present results of two Phase II trials evaluating ALIMTA in combination with chemotherapy, radiation

Genentech to present new data for targeted cancer medicines at 46th ASCO

Data from Phase 3 clinical trials of PROVENGE in advanced prostate cancer to be presented at ASCO 2010

Long-term data demonstrates clinical benefits of Exelixis XL184 for medullary thyroid cancer

Canadian Cancer Statistics 2010 focuses on care, support for dying patients

A.P. Pharma receives Nasdaq non-compliance notice

Allergy sufferers can save out-of-pocket costs by visiting urgent care and retail health clinics instead of ER

Research shows improved treatment of severe epilepsy reduces overall cost of the condition

Studies suggest potent therapeutic effects of rufinamide in bipolar disorder, depressive and anxiety disorders

DanActive drink reduces rate of common sicknesses in daycare children, say researchers

Flibanserin benefits pre-menopausal women with Hypoactive Sexual Desire Disorder

Columbia Laboratories renews license and supply agreement with Merck Serono

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News